CAS 151533-22-1 L-5-Methyltetrahydrofolate Calcium L-5-Mthf-Ca Powder

• Customization: Available
• CAS No.: 151533-22-1
• Formula: C20h27can7o6
• Model NO.: top quality
• EINECS: 691-636-3
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Technical
• Colour: White
• Molecular Formula: C20h27can7o6
• Molecular Weight: 501.56
• Grade Standard: Medical Grade
• MOQ: 100g
• COA: Pls Contact Senwayer Freely
• Storge: 2-8 Degree
• Exp.: 24 Months
• Transport Package: 1kg/Bag, 25kg/Drum
• Specification: MOQ: 100g
• Trademark: senwayer
• Origin: China
• HS Code: 2601111000
• Production Capacity: 50kg Per Month

Product Description

99% Raw Material Levomefolate Calcium 151533-22-1 Pharmaceutical Powder Levomefolate Calcium

Product Introduction
Calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) is a synthetic derivative of folic acid, the predominant, naturally occurring form of folate. L-5-methyltetrahydrofolate, also known as levomefolic acid, is the primary biologically active form of folate. It is involved in many important in vivo process including DNAreproduction, the cysteine cycle and the regulation of homocysteine. It is also the form found in circulation and transported across membranes into tissues and across the blood-brain barrier. It can be used for the treatment of major depressive disorder, cardiovascular disease and cancer. It can be used for the treatment of hyperhomocysteinemia regularly found in hemodialysis patients.  


Function
Mainly for folic acid antagonists (such as methotrexate, pyrimethamine, benzyl cefalexin and trimethoprim) antidote, it's usually used for prevention of methotrexate dose or overdose treatment caused severe toxic effects.
Folic acid treatment of the following diseases, such as inflammatory diarrhea and protein-energy malnutrition (poor nutrition), pregnancy or infancy megaloblastic anemia caused by poor.
As adjuvant therapy for colon cancer, rectal cancer.
Combined with 5-FU and treatment of digestive tract tumors or other 5-FU-sensitive tumors. High-dose CF used in conjunction with 5-FU (LF), the basic programme is currently the treatment of colon and rectal cancer.
For children with leukemia, lymphoma, and osteosarcoma, such as high dose MTX treatment when rescued.  

 

Batch No.	171121	Quantity	8.5kgs
Mfg. Date	Nov. 21, 2017	Package	As required
Rep. Date	Nov. 25, 2017	Exp. Date	Nov. 20, 2019
Items	Standards		Results
Appearance	White or off-white solid powder		Complies
Identification	By IR		Complies
	By HPLC		Complies
Polymorphic Form	Polymorphic form 1		Complies
Melting Point	211ºC~216ºC		212.8ºC~214.9ºC
Water Content	≤ 0.50%		0.10%
Heavy Metals	≤ 20ppm		Complies
Residue on Ignition	≤ 0.20%		0.09%
Related Substance	Any single impurity: ≤0.10%		0.06%
	Total Impurities: ≤1.00%		0.16%
Assay                  (on the anhydrous basis)	98.0%~102.0%		99.94%
Particle Size	D90: ≤100µm		Complies
Reference Standard	In-house Standard
Conclusion	The product complied to In-house standard.
Storage	Preserve in tight,light-resistant containers in a cool place

Related products

Product Name	CAS No.	Product Name	CAS No.
Lufenuron	103055-07-8	Toltrazuril	69004-03-1
Nitenpyram	120738-89-8	Praziquantel/Biltricide	55268-74-1
Fenbendazole	43210-67-9	Tetramisole Hcl	5086-74-8
Levamisole	14769-73-4	Ponazuril	9004-4-2
Diclazuril	101831-37-2	Florfenicol	73231-34-2
Ivermectin	70288-86-7	Enrofloxacin Hcl	112732-17-9
Albendazole	54965-21-8	Mebendazole	31431-39-7

 

Warnings

All products are exported for Lab & Research use in legal and Non-patented area only. Products may not be used in human or animals. Individuals are fully responsible for all consequences arising therefrom.